CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy
CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy
复制标题
DOI：
10.1093/infdis/jiv504
复制
发表时间：
2016-03-01
影响因子：
6.4
通讯作者：
Kuritzkes, Daniel R.
中科院分区：
文献类型：
--
作者：
Henrich, Timothy J.;Hanhauser, Emily;Kuritzkes, Daniel R.
我们在114名接受抗逆转录病毒抑制治疗的艾滋病临床试验组参与者中进行了一项病例对照研究，研究CCR5-Delta 32杂合性与人类免疫缺陷病毒1型（HIV-1）库大小、淋巴细胞活化和CCR5表达的关系。总的来说，在这些参数中没有发现组间的显著差异。然而，较高水平的CCR5表达与较低数量的细胞相关HIV-1 RNA相关。CCR5- delta 32杂合性、CCR5表达与HIV-1持久性标志物之间的关系可能是复杂的，并可能受到ART持续时间等因素的影响。
We conducted a case-controlled study of the associations of CCR5-Delta 32 heterozygosity with human immunodeficiency virus type 1 (HIV-1) reservoir size, lymphocyte activation, and CCR5 expression in 114 CCR5(Delta 32/WT) and 177 wild-type CCR5 AIDS Clinical Trials Group participants receiving suppressive antiretroviral therapy. Overall, no significant differences were found between groups for any of these parameters. However, higher levels of CCR5 expression correlated with lower amounts of cell-associated HIV-1 RNA. The relationship between CCR5-Delta 32 heterozygosity, CCR5 expression, and markers of HIV-1 persistence is likely to be complex and may be influenced by factors such as the duration of ART.